Access

Letter

Nature Medicine 11, 786 - 790 (2005)
Published online: 5 June 2005 | doi:10.1038/nm1258

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

Steven M Jones1,2,9, Heinz Feldmann1,3,9, Ute Ströher1,3, Joan B Geisbert4, Lisa Fernando1, Allen Grolla1, Hans-Dieter Klenk5, Nancy J Sullivan6, Viktor E Volchkov7, Elizabeth A Fritz4, Kathleen M Daddario8, Lisa E Hensley4, Peter B Jahrling4 & Thomas W Geisbert4

Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus (MARV). Here, we developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges. Notably, vaccine vector shedding was not detectable in the monkeys and none of the animals developed fever or other symptoms of illness associated with vaccination. The EBOV vaccine induced humoral and apparent cellular immune responses in all vaccinated monkeys, whereas the MARV vaccine induced a stronger humoral than cellular immune response. No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Will we have and why do we need an Ebola vaccine?

Nature Medicine News and Views (01 Dec 2000)

A single shot against Ebola and Marburg virus

Nature Medicine News and Views (01 Jul 2005)

RESEARCH

Immunization for Ebola virus infection

Nature Medicine Article (01 Jan 1998)

See all 2 matches for Research